Cargando…
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
Immunotherapy has become the standard of care for non-small cell lung cancer (NSCLC), either in combination or monotherapy. However, there are still some patients who cannot benefit from it. Immunization strategies for NSCLC are based on the expression of PD-L1 on tumor cells and TMB, and although t...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900392/ https://www.ncbi.nlm.nih.gov/pubmed/35255999 http://dx.doi.org/10.1186/s40364-022-00355-7 |